MINNEAPOLIS, March 4 /PRNewswire-FirstCall/ -- GelStat Corporation (BULLETIN BOARD: GSAC) , a leading innovator in over-the-counter (OTC) consumer health care products, today announced that it has engaged Wall Street Consultants Corp., headquartered in New York City, to manage its investor relations campaign.
Wall Street Consultants Corp. (WSCC), founded in 1999, is a company comprised of “institutional” Wall Street professionals (institutional sales professionals, portfolio managers and research analysts), with an average of 18-years experience in the investment field. Joe Zappulla, Wall Street Consultants Corp’s founder, president and CEO, commented, “GelStat is addressing common ailments, using their novel anti-inflammatory compounds in combination with advanced delivery systems to introduce products with better efficacy, safety and convenience relative to existing OTC health care products. The Company has been highly effective in placing its first product, GelStat Migraine, in 16,000 retail locations, including eight of the top twelve national drugstore chains in just a few months, and expects to enter the remaining chains in 2005, as well as supermarkets and mass market retailers. GelStat’s highly experienced management team has developed an efficient manufacturing, fulfillment and accounting infrastructure to handle multiple product rollouts. Its operations are designed to enable the introduction of an extended line of effective products, each with robust margins.
“GelStat has spent the past three years developing the advanced formulations and delivery systems required to create a portfolio of innovative and effective over-the-counter health care products. Having now secured national retail distribution for the first of those products, our focus for 2005 is on driving consumer awareness and trial of GelStat Migraine. However, we believe it is also important to expand awareness of the company within the investment community, and so have engaged an investor relations consultant whose team is comprised of highly experienced professionals in the institutional investment process,” said Stephen Roberts, M.D., chairman and CEO of GelStat.
About GelStat Corporation
GelStat Corporation is a consumer health care company dedicated to the cost-effective development and marketing of advanced OTC health care products. Development efforts are focused on large markets where GelStat products can offer improved efficacy, safety, and/or convenience over existing OTCs. GelStat is committed to building a portfolio of products with significant commercial potential.
The Company has initiated early marketing efforts for “GelStat(TM) Arthritis”, “GelStat(TM) Sinus” and “GelStat(TM) Sleep”, and believes that each of these products performs well and is effective for its intended use. Between 40 and 70 million Americans have some form of arthritis according to the National Institutes of Health. The National Institute of Allergy and Infectious Disease estimates that 37 million Americans are affected by sinusitis every year, with at least 20 million more suffering from allergies. Approximately 70 million Americans are reported to be “problem sleepers”. For more information, visit http://www.gelstat.com/ .
About GelStat Migraine
GelStat Migraine is a new, patent pending OTC medication for acute relief from the pain and associated symptoms of migraine and migraine-like headaches. In general, older OTC headache medications are based on aspirin or other non- steroidal anti-inflammatory drugs (NSAIDs) with these agents estimated to exhibit an effect in approximately 25 percent of those with moderate to severe migraine.
The initial clinical trial of GelStat Migraine showed it to be effective for 83 percent of those with moderate to severe migraine. Further details regarding this initial clinical trial are available on the Company’s website ( http://www.gelstat.com/ )
This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statement other than a statement of historical fact should be considered a forward- looking statement. Such forward-looking statements are based on the Company’s current expectations and involve known and unknown risks, uncertainties, or other factors which may cause actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation and does not intend to release publicly any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect unanticipated events or developments.
Contact: Investor Inquiries or Media Inquiries Yvonne L. Zappulla Tony Carideo Managing Director President Wall Street Consultants Corp. The Carideo Group, Inc. 212-681-4108 612-317-2880 Yvonne@WallStreetIR.comTony@CarideoGroup.com
GelStat Corporation
CONTACT: Investor Inquiries, Yvonne L. Zappulla, Managing Director ofWall Street Consultants Corp., +1-212-681-4108, Yvonne@WallStreetIR.com ,or Media Inquiries, Tony Carideo, President of The Carideo Group, Inc.,+1-612-317-2880, Tony@CarideoGroup.com
Web site: http://www.gelstat.com/